Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytok...

Descripción completa

Detalles Bibliográficos
Autores principales: Seber, Adriana, de CastroJunior, Claudio Galvão, Kerbauy, Lucila N., Hirayama, Alexandre V., Bonfim, Carmem, Fernandes, Juliana Folloni, Souza, Mair, Schafell, Rony, Nabhan, Samir, Loggetto, Sandra Regina, Simões, Belinda Pinto, Rocha, Vanderson, de Lima, Marcos, Guerino-Cunha, Renato L., Bittencourt, Henrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606700/
https://www.ncbi.nlm.nih.gov/pubmed/34794791
http://dx.doi.org/10.1016/j.htct.2021.09.002
Descripción
Sumario:Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.

Ejemplares similares